Atrial fibrillation, statins, and liver risk: 3 questions for your next visit (2026)

The useful change this week is a fuller checklist for chronic-disease visits. A new atrial-fibrillation care framework asks clinicians to document risk and prevention more consistently. A large review shows why statin users still need the rest of their cardiovascular risk plan. A new diabetes-and-liver study compares two commonly used medicines without giving patients a reason to switch on their own.

Each update points to a question you can take to your next appointment.

Quick view: what deserves attention now

Update	What changed	Who may care	Action window	Appointment question
Atrial fibrillation care measures	The ACC and AHA published a set of 5 performance measures and 16 quality measures based on strong or avoid-harm recommendations from the 2023 AF guideline. 1	People with atrial fibrillation, especially anyone newly diagnosed or taking an anticoagulant	At the next heart visit or medication review	Has my stroke risk score been documented this year, and does my kidney function affect my treatment?
Residual risk while taking a statin	A systematic review estimated remaining cardiovascular event rates among adults taking statins, with higher rates in people who already had atherosclerotic cardiovascular disease. 2	People taking statins or managing high cholesterol, diabetes, high blood pressure, or known ASCVD	Bring your medication list and latest cholesterol and blood-pressure readings to the next prevention visit	Which risk factors still need attention alongside my statin?
Tirzepatide and injectable semaglutide	In adults with type 2 diabetes and overweight or obesity, the two medicines had similar rates of major liver outcomes over about 17 months in a retrospective comparison. 3	People using, considering, or comparing these medicines, especially with MASLD	Review goals, side effects, access, and liver history before any medication change	Which outcome matters most in my case: glucose, weight, cardiovascular risk, liver risk, side effects, or cost?

1. Atrial fibrillation care is getting a more complete checklist

Atrial fibrillation, or AF, is an irregular heart rhythm that can raise the risk of stroke and heart failure. On August 17, the American Heart Association listed a new ACC/AHA AF performance-measures document in Circulation: Population Health and Outcomes. 4

The full document contains 5 performance measures for public reporting or formal quality programs and 16 quality measures for local improvement work. The measures were drawn from Class 1 recommendations, which the guideline treats as recommended, and Class 3 recommendations, which identify care with no benefit or potential harm. The measure set implements the 2023 ACC/AHA/ACCP/HRS AF guideline; it functions as a way to check whether recommended care is happening across hospitals and clinics. 1

For patients, five items are especially useful to recognize:

A newly diagnosed patient should receive a basic clinical evaluation.
Ongoing care should include secondary prevention, such as physical activity, weight management, smoking cessation, alcohol moderation, and blood-pressure control when appropriate.
A validated stroke-risk score should be documented each year.
A direct oral anticoagulant, or DOAC, should be prescribed when the clinical indication supports it.
People with AF who also undergo a coronary procedure need a careful review of anticoagulant and antiplatelet combinations.

The quality measures add patient-centered decisions to that checklist. The document calls for shared decision-making about rate control—slowing the heart rate—and rhythm control—trying to restore and maintain a regular rhythm. It also addresses medication choices in people with a mechanical heart valve, mitral stenosis, severe chronic kidney disease, or heart failure with reduced ejection fraction. 1

Your next step: bring your current medication list, the date of your last kidney-function test, and any home blood-pressure or pulse readings. Ask:

Has my stroke-risk score been reviewed this year?
What is the purpose of each blood thinner or heart-rhythm medicine I take?
Does my kidney function, valve history, or heart-failure history affect the choice or dose?
Are rate control and rhythm control both reasonable options for me?

The document gives clinicians a shared checklist. Your personal treatment still depends on your diagnoses, test results, bleeding risk, preferences, and goals.

2. A statin lowers risk while the rest of prevention still matters

Statins lower low-density lipoprotein cholesterol and remain a foundation of cardiovascular prevention. A systematic review and meta-analysis published August 20 examined residual atherosclerotic cardiovascular disease, or ASCVD, risk among adults who were already taking statins. The review included observational studies published from 2013 through 2023 and reported event rates per 1,000 person-years. 2

The pooled rate for a combined outcome of major cardiovascular events or death from any cause was 12.3 events per 1,000 person-years across the overall population. The estimate was 6.4 per 1,000 person-years among adults at risk for ASCVD and 15.8 per 1,000 person-years among adults with prior ASCVD. The review also estimated 8.23 heart attacks, 6.0 ischemic strokes, 4.3 cardiovascular deaths, and 7.4 coronary revascularizations per 1,000 person-years in the overall population. 2

A rate per 1,000 person-years describes events across a group and a period of follow-up. It does not calculate your personal chance this year. The wide ranges between the underlying studies also show how much age, prior disease, treatment intensity, follow-up, and healthcare setting can change the estimate.

The patient-facing point is a medication review, not a verdict on statins. A person can take a statin consistently and still have important risks related to blood pressure, smoking, diabetes, kidney disease, weight, physical activity, sleep, family history, or cholesterol levels that remain above the agreed goal. The review was observational, so the pooled rates describe risk among real-world statin users rather than testing whether one treatment plan caused a particular outcome. The PubMed record lists author affiliations with Merck & Co. and Lumanity, which gives readers another reason to discuss how the findings fit their own treatment plan rather than treating the pooled number as a personal target. 2

Your next step: gather your latest LDL cholesterol, blood pressure, A1c if you have diabetes, smoking status, and medication list. Ask:

What is my current ASCVD risk category?
What LDL cholesterol goal fits my history?
Which risk factor deserves the next improvement—blood pressure, glucose, smoking, activity, weight, sleep, or medication adherence?
Should we review my statin dose, side effects, or the need for another cholesterol medicine?

Keep taking prescribed medicines as directed while you arrange that conversation. A new paper is a reason to review the plan with your clinician; it is not a reason to stop or change a statin without guidance.

3. Tirzepatide and semaglutide showed similar liver outcomes in a real-world comparison

A study published August 19 compared tirzepatide with injectable semaglutide in adults with type 2 diabetes and overweight or obesity. The researchers used a retrospective target-trial emulation, a method that uses health-record data to imitate some features of a clinical trial. The study analyzed new users in the TriNetX global network and used propensity-score matching to balance measured starting characteristics. 3

The primary outcome was a composite called major adverse liver outcomes, or MALO: cirrhosis, decompensated liver events, or hepatocellular carcinoma. Over a median follow-up of about 17 months, the estimated rate was 4.05 per 1,000 person-years for tirzepatide and 4.04 per 1,000 person-years for injectable semaglutide. The hazard ratio was 1.04, with a 95% confidence interval from 0.88 to 1.23. In the subgroup with MASLD—metabolic dysfunction-associated steatotic liver disease—the rates were 9.97 and 10.03 per 1,000 person-years, with a hazard ratio of 1.03 and a 95% confidence interval from 0.75 to 1.42. 3

Tirzepatide produced about 1.1 kg/m² more BMI reduction than injectable semaglutide in this analysis. The liver-outcome comparison stayed similar in additional analyses. The study therefore gives clinicians a way to discuss several treatment goals together: glucose control, weight, liver risk, cardiovascular risk, side effects, access, and cost.

The design leaves important questions open. Health-record comparisons can balance measured characteristics while leaving unmeasured differences between treatment groups. The follow-up lasted about a year and a half, so the results describe short- to medium-term outcomes. The comparison also studied adults with type 2 diabetes and overweight or obesity; the findings do not automatically apply to people without diabetes, people at a different weight, or people using a different formulation.

Your next step: if you take or are considering one of these medicines, write down the outcome you most want to improve and the problems you most want to avoid. Ask:

How do my glucose readings, A1c, weight, liver tests, and symptoms fit together?
Do I have MASLD or another liver condition that changes our monitoring plan?
Which medicine best fits my response, side effects, kidney function, other medicines, coverage, and daily routine?
What should I do if nausea, poor appetite, dehydration, or low glucose affects my eating or medicines?

A medication comparison can inform a shared decision. Your clinician still needs to match the medicine to your medical history and treatment goals.

Questions to take to your next appointment

If you have AF: Has my annual stroke-risk score been documented, and do my kidney or valve conditions affect my treatment choices?
If you take a statin: What is my current ASCVD risk, and which additional risk factor should we address next?
If you have diabetes and liver risk: How should we track A1c, weight, liver tests, symptoms, and medication side effects together?
For any new research: Which parts of the study population and follow-up period resemble my own situation?

The shared lesson is simple: a population number becomes useful when your care team connects it to your diagnoses, medicines, symptoms, and goals. Bring the trend and the question to the visit.

This brief is for appointment preparation and caregiver discussion. It does not replace individualized medical advice.

参考ソース

1
2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillationjacc.org
2
Residual Atherosclerotic Cardiovascular Disease Risk in Statin Users: A Systematic Review and Meta-Analysispubmed.ncbi.nlm.nih.gov
3
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetespubmed.ncbi.nlm.nih.gov
4
Council on Cardiovascular and Stroke Nursing publication listingprofessional.heart.org